Table 2 Number and percent of Mendelian randomization analyses per grading category by cancer group
From: Systematic review of Mendelian randomization studies on risk of cancer
Cancer group | Robust evidence | Probable evidence | Suggestive evidence | Insufficient evidence | Non-evaluable |
|---|---|---|---|---|---|
Head and neck | 0 (0) | 2 (0.73) | 0 (0) | 10 (0.98) | 23 (0.72) |
Esophageal | 1 (1.15) | 1 (0.36) | 0 (0) | 8 (0.79) | 28 (0.88) |
Stomach | 0 (0) | 3 (1.09) | 0 (0) | 7 (0.69) | 20 (0.63) |
Small intestine | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 36 (1.13) |
Colorectal | 2 (2.3) | 31 (11.27) | 21 (23.6) | 75 (7.38) | 156 (4.88) |
Liver and biliary tract | 3 (3.45) | 2 (0.73) | 1 (1.12) | 5 (0.49) | 29 (0.91) |
Pancreatic | 0 (0) | 15 (5.45) | 2 (2.25) | 42 (4.13) | 587 (18.34) |
Lung | 14 (16.09) | 46 (16.73) | 14 (15.73) | 148 (14.57) | 412 (12.88) |
Skin/melanoma | 3 (3.45) | 7 (2.55) | 0 (0) | 14 (1.38) | 136 (4.25) |
Sarcomas | 1 (1.15) | 1 (0.36) | 0 (0) | 3 (0.3) | 1 (0.03) |
Breast | 29 (33.33) | 40 (14.55) | 20 (22.47) | 140 (13.78) | 357 (11.16) |
Cervical | 0 (0) | 2 (0.73) | 1 (1.12) | 3 (0.3) | 14 (0.44) |
Endometrial | 11 (12.64) | 7 (2.55) | 0 (0) | 10 (0.98) | 31 (0.97) |
Ovarian | 9 (10.34) | 35 (12.73) | 11 (12.36) | 180 (17.72) | 347 (10.84) |
Prostate | 1 (1.15) | 15 (5.45) | 6 (6.74) | 57 (5.61) | 278 (8.69) |
Kidney | 2 (2.3) | 9 (3.27) | 1 (1.12) | 17 (1.67) | 55 (1.72) |
Bladder and urinary tract | 2 (2.3) | 6 (2.18) | 5 (5.62) | 23 (2.26) | 116 (3.62) |
Central nervous system | 0 (0) | 22 (8) | 1 (1.12) | 110 (10.83) | 201 (6.28) |
Thyroid | 1 (1.15) | 4 (1.45) | 0 (0) | 9 (0.89) | 34 (1.06) |
Leukemias and lymphomas | 2 (2.3) | 16 (5.82) | 2 (2.25) | 125 (12.3) | 213 (6.66) |
Any cancer/mixed | 6 (6.9) | 11 (4) | 4 (4.49) | 30 (2.95) | 126 (3.94) |
Total | 87 (100) | 275 (100) | 89 (100) | 1016 (100) | 3200 (100) |